Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APEN Apollo Endosurgery		$9.94	$3.49 ▼ $10.30	$579.72M	2.31	1.43 million shs	1.66 million shs
BVS Bioventus	$6.77 +1.7%	$6.79	$5.47 ▼ $14.38	$556.12M	0.86	457,206 shs	2.03 million shs
CATX Perspective Therapeutics	$3.76 +3.9%	$2.82	$1.60 ▼ $16.55	$279.10M	1.09	1.10 million shs	4.16 million shs
FNA Paragon 28	$13.11 +0.1%	$13.11	$4.65 ▼ $13.13	$1.10B	1.47	1.14 million shs	19.38 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APEN Apollo Endosurgery	0.00%	0.00%	0.00%	0.00%	0.00%
BVS Bioventus	+1.65%	+3.36%	+3.68%	-25.03%	+20.89%
CATX Perspective Therapeutics	+3.87%	+8.67%	+45.74%	+70.91%	-60.46%
FNA Paragon 28	0.00%	0.00%	0.00%	+0.54%	+108.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APEN Apollo Endosurgery	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BVS Bioventus	3.35 of 5 stars	3.3	0.0	0.0	0.0	2.3	4.2	1.3
CATX Perspective Therapeutics	3.1527 of 5 stars	4.6	1.0	0.0	0.0	3.0	2.5	0.0
FNA Paragon 28	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APEN Apollo Endosurgery	0.00	N/A	N/A	N/A
BVS Bioventus	2.67	Moderate Buy	$14.33	111.72% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	233.92% Upside
FNA Paragon 28	2.20	Hold	$12.75	-2.71% Downside

Current Analyst Ratings Breakdown

Latest APEN, FNA, BVS, and CATX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
5/7/2025	BVS Bioventus	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$15.00
4/7/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $10.00
3/31/2025	CATX Perspective Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APEN Apollo Endosurgery	$76.86M	0.00	N/A	N/A	$0.69 per share	0.00
BVS Bioventus	$567.70M	0.98	$0.54 per share	12.58	$2.80 per share	2.42
CATX Perspective Therapeutics	$1.43M	195.17	N/A	N/A	$2.67 per share	1.41
FNA Paragon 28	$256.18M	4.29	N/A	N/A	$2.05 per share	6.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APEN Apollo Endosurgery	-$39.84M	-$1.02	N/A	N/A	N/A	-51.84%	-89.48%	-33.76%	N/A
BVS Bioventus	-$156.23M	-$0.48	N/A	14.72	N/A	-7.11%	15.61%	4.01%	N/A
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/11/2025 (Estimated)
FNA Paragon 28	-$57.53M	-$0.63	N/A	N/A	N/A	-25.31%	-37.90%	-18.22%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APEN Apollo Endosurgery	N/A	N/A	N/A	N/A	N/A
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
FNA Paragon 28	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APEN Apollo Endosurgery	1.04	2.35	1.89
BVS Bioventus	1.85	1.41	0.99
CATX Perspective Therapeutics	N/A	9.60	9.60
FNA Paragon 28	0.79	3.50	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APEN Apollo Endosurgery	76.01%
BVS Bioventus	62.94%
CATX Perspective Therapeutics	54.66%
FNA Paragon 28	63.57%

Insider Ownership

Company	Insider Ownership
APEN Apollo Endosurgery	17.30%
BVS Bioventus	33.00%
CATX Perspective Therapeutics	3.72%
FNA Paragon 28	15.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APEN Apollo Endosurgery	202	57.97 million	47.94 million	Not Optionable
BVS Bioventus	1,200	82.14 million	54.46 million	Not Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
FNA Paragon 28	343,000	83.94 million	70.89 million	Optionable

APEN, FNA, BVS, and CATX Headlines

Recent News About These Companies

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Investors to Reach Out

June 17, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Stockholders to Reach Out

June 15, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Stockholders to Connect

June 12, 2025 | accessnewswire.comA

Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

June 10, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Shareholders to Inquire about Securities Investigation

June 8, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Shareholders to Connect

June 5, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Shareholders to Reach Out

June 3, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Shareholders to Learn More About the Investigation

June 1, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Stockholders to Inquire about Securities Investigation

May 29, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Investors to Learn More About the Investigation

May 27, 2025 | accessnewswire.comA

Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 25, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Investors to Connect

May 22, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Stockholders to Inquire about Securities Investigation

May 20, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Stockholders to Reach Out

May 18, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Stockholders to Connect

May 15, 2025 | accessnewswire.comA

Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 13, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Stockholders to Learn More About the Investigation

May 11, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Investors to Inquire about Securities Investigation

May 8, 2025 | accessnewswire.comA

Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 6, 2025 | accessnewswire.comA

Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal

May 5, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APEN, FNA, BVS, and CATX Company Descriptions

Apollo Endosurgery NASDAQ:APEN

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Bioventus NYSE:BVS

$6.77 +0.11 (+1.65%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.76 -0.01 (-0.15%)

As of 06/27/2025 05:54 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Perspective Therapeutics NYSE:CATX

$3.76 +0.14 (+3.87%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.81 +0.05 (+1.36%)

As of 06/27/2025 08:00 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)

Closing price 04/17/2025

Extended Trading

$13.10 0.00 (0.00%)

As of 04/17/2025 05:47 PM Eastern

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time